Significant’ findings suggest potential for effective, non-toxic treatment for this aggressive childhood cancer
Dublin, Ireland: Researchers investigating new treatments for neuroblastoma – one of the most common childhood cancers – have found that a combination of two drugs made tumours disappear in mice, making it more effective than any other drugs tested in these animals.
Professor Murray Norris, deputy director of the Children’s Cancer Institute Australia for Medical Research, Sydney, Australia, told the 30th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today (Thursday) that the findings were unusual and highly significant. But he warned that it would be some time before the drug combination would be tested in children and, if successful, made available more widely to treat children with this disease, even though both drugs are currently undergoing clinical trial in a range of adult cancers.
Neuroblastoma is one of the most common childhood cancers and is the leading single cause of cancer deaths in children under five. It is frequently found in the adrenal glands on top of the kidneys. Despite using intensive treatment regimens, children with the most aggressive forms of neuroblastoma have less than 50% survival rates.
Prof Norris said: “To study neuroblastoma in the laboratory, we use a genetically modified neuroblastoma mouse model that closely recapitulates clinical features of the disease, and these mice spontaneously develop neuroblastomas within weeks after birth. We have found that when we combined CBL0137 and panobinostat to treat mice bearing neuroblastomas, the tumours disappeared and never came back during the entire experiment, whereas the tumours continued to grow in mice that received either no treatment or only single drug treatment.
“This is a highly significant finding as this drug combination is the most effective therapy that we have observed in this neuroblastoma mouse model. It is unusual to see this effect, especially in these mice where neuroblastoma develops within seven weeks of birth and is aggressive in nature. In fact, the CBL0137/panobinostat combination is more effective than any other current clinical chemotherapy combinations that our laboratory has tested in these mice.”
CBL0137, which belongs to a new class of drugs called curaxins, attacks the structure of cancer cells but is a safe drug that does not damage DNA in normal cells. Prof Norris and his colleagues used RNA sequencing technology that can detect drug-induced changes in tumours, to see how the combination of CBL0137 and panobinostat stopped neuroblastoma growing.
“Our results suggest that these drugs work through two different mechanisms that offer a two-pronged attack. One of these mechanisms appears to be a direct attack on the cancer cells themselves, killing them by inhibiting DNA repair; then a second mechanism is involved in inducing a robust immune response. This is very exciting and will hopefully facilitate the clinical development of effective and non-toxic therapies for childhood cancer,” he said.
“Unlike conventional chemotherapy drugs that interact with DNA, CBL0137 is non-DNA damaging and therefore is comparatively less toxic. Developing CBL0137 combination therapies has the potential to reduce acute and long-term side effects and increase the quality of life of children with cancer while extending the survival rates of these children. Another important implication is that the CBL0137/panobinostat combination can activate an immune response which may significantly boost the efficacy of immunotherapy drugs that are otherwise ineffective for neuroblastoma.”
The researchers are continuing their laboratory work to investigate further how the combination of these two drugs activates the immune response, and to test CBL0137/panobinostat with other immunotherapy drugs in mice. A phase I clinical trial of CBL0137 in children with neuroblastoma and other difficult-to-treat childhood cancers is planned to start in 2019, following the completion of a phase I clinical trial of the drug in adults with solid cancers and previously treated blood cancers. The trial of CBL0137 alone in children will need to be completed successfully before a trial testing the combination of the two drugs can be planned, which means it will be a few years before it is known whether the treatment can be used more widely.
Further lab research by Prof Norris and his colleagues also showed that CBL0137 and panobinostat slowed the growth of aggressive childhood leukaemias in mice and significantly extended survival.
In addition to approving CBL0137 for phase I clinical trials in adults, the FDA has already approved panobinostat for multiple myeloma and it is being tested in clinical trials for a range of other cancers.
Learn more:Â Drug combination makes cancer disappear in mice with neuroblastoma
The Latest on: Neuroblastoma
[google_news title=”” keyword=”neuroblastoma” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Neuroblastoma
- Study gives more insight into neuroblastoma treatmenton May 17, 2024 at 1:50 am
New treatment strategy for neuroblastoma may involve focusing on RNA. alterations linked to the condition, according to recent study from the University of Chicago. Researchers ha ...
- Yttrium 90-labelled edotreotide by Progenics Pharmaceuticals for Neuroblastoma: Likelihood of Approvalon May 16, 2024 at 7:11 pm
Yttrium 90-labelled edotreotide is under clinical development by Progenics Pharmaceuticals and currently in Phase II for Neuroblastoma.
- Scientists discover new insight into the genetic pathway of neuroblastomaon May 15, 2024 at 12:46 pm
Scientists have discovered a new insight into the genetic pathway of childhood cancer, offering new hope for tailored treatments. Researchers from the University of Sheffield have created a stem cell ...
- Stem Cells Shed Insights into Neuroblastomaon May 14, 2024 at 10:02 pm
Their development of a stem cell model aims to probe the roots of neuroblastoma, a cancer predominantly impacting infants and toddlers. () Neuroblastoma is the most common childhood tumor occurring ...
- Stem Cell Model Illuminates Genetic Drivers of Neuroblastomaon May 14, 2024 at 7:55 pm
These cells carried genetic changes often seen in aggressive neuroblastoma tumours. Using genomics analysis and advanced imaging techniques, the researchers found that the altered cells started ...
- Drug targeting RNA modifications shows promise for treating neuroblastomaon May 3, 2024 at 12:10 pm
Neuroblastoma is a common pediatric cancer that originates in developing nerve cells outside the brain. While increasingly intensive treatments have improved the survival of patients with high-risk ...
- A new era for treating high-risk neuroblastoma – research advances to look out for in 2024on April 24, 2024 at 5:55 am
It's an exciting time for research into high-risk neuroblastoma. Over the past year, multiple trials testing new treatments showed promising results, and in 2024, new trials are expected to open to ...
- Ten Challenges in the Management of Neuroblastomaon April 21, 2024 at 5:00 pm
Current high-risk neuroblastoma protocols involve a multimodality therapy approach and include an induction chemotherapy regime, surgical resection of the primary tumor, high-dose myeloablative ...
- Cyclophosphamide Therapy in Childhood Neuroblastomaon April 4, 2024 at 5:00 pm
Children under fifteen years of age, presenting a tissue diagnosis of neuroblastoma at 1 of 9 pediatric centers in a Cooperative group,∥ were evaluated for inclusion in the study. Patients with ...
via Bing News